Elubrixin tosylate structure
|
Common Name | Elubrixin tosylate | ||
---|---|---|---|---|
CAS Number | 960495-43-6 | Molecular Weight | 635.51200 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C24H25Cl2FN4O7S2 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Elubrixin tosylateElubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation[1][2][3]. |
Name | 1-(2-chloro-3-fluorophenyl)-3-(4-chloro-2-hydroxy-3-piperazin-1-ylsulfonylphenyl)urea,4-methylbenzenesulfonic acid |
---|---|
Synonym | More Synonyms |
Description | Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin tosylate inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin tosylate has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation[1][2][3]. |
---|---|
Related Catalog | |
Target |
CXCR2 IL-8 |
In Vitro | Elubrixin has an inhibitory effect on neutrophils in a dose-dependent fashion[1]. |
References |
Molecular Formula | C24H25Cl2FN4O7S2 |
---|---|
Molecular Weight | 635.51200 |
Exact Mass | 634.05300 |
PSA | 185.39000 |
LogP | 6.83260 |
~% Elubrixin tosylate CAS#:960495-43-6 |
Literature: SMITHKLINE BEECHAM CORPORATION Patent: WO2007/150015 A2, 2007 ; Location in patent: Page/Page column 10-11 ; WO 2007/150015 A2 |
UNII-13FVR7WD4P |
Elubrixin tosylate |